Ernest G Smith

US Patent:

7067251, Jun 27, 2006

Filed:

Mar 28, 2001

Appl. No.:

09/818991

Inventors:

Maurice Zauderer - Pittsford NY, US
Ernest S. Smith - Ontario NY, US

Assignee:

University of Rochester - Rochester NY

International Classification:

C12Q 1/68
C12N 15/86
C12N 15/87
C07H 21/04

US Classification:

435 6, 435 5, 4353201, 435 691, 435DIG 1, 435DIG 4, 435DIG 14, 435DIG 17, 536 231, 536 235

Abstract:

The present invention relates to a high efficiency method of introducing DNA into linear DNA viruses such as poxvirus, a method of producing libraries in linear DNA viruses such as poxvirus, and methods of selecting polynucleotides of interest based on cell nonviability or other phenotypes.

US Patent:

7222581, May 29, 2007

Filed:

Nov 15, 2006

Appl. No.:

11/560068

Inventors:

Ernest Mayo Smith - Sanford FL, US
David Gregory Chapman - Chuluota FL, US

Assignee:

Water Bonnet Manufacturing, Inc. - Casselberry FL

International Classification:

B63B 17/02

US Classification:

114361, 296 9621

Abstract:

A transition device for providing a smooth corner of a pair of angular oriented interconnected windshields on a boat, the boat having a forward facing or front windshield and a side facing windshield, both the windshields being mounted in a formed aluminum molding. The transition device comprises a first element attached to the molding of the forward facing windshield at an upper end of the joint and terminating at the joint in a ball and a second element attached to the molding of the side facing windshield at the upper end of the joint and terminating in a socket. The ball and the socket are shaped and sized to fit together to form a smooth transition at the upper end of the joint so that the corner joint appears to have a ball and socket joint.

US Patent:

7654092, Feb 2, 2010

Filed:

Jul 18, 2006

Appl. No.:

11/488562

Inventors:

William R. Ryan - Oviedo FL, US
Ernest W. Smith - Orlando FL, US

Assignee:

Siemens Energy, Inc. - Orlando FL

International Classification:

F02C 9/22
F02C 9/34

US Classification:

60776, 60 39281, 60734

Abstract:

A fuel modulation system usable in can-annular combustor systems of turbine engines for more efficiently managing fuel flow to reduce the amount of NOwhile maintaining appropriate combustor flame temperatures. The fuel modulation system controls individual inline modulation valves in cooperation with a overall stage control valve to bring a turbine engine through the startup phase and to maintain operating conditions at a load set point while reducing NOvariability between baskets by using individual combustor dynamic pressure measurements. The fuel modulation system may be managed such that individual inline modulation valves remain within a predetermined range of positions relative to a nominal position to reduce NOvariability.

US Patent:

7807168, Oct 5, 2010

Filed:

Apr 9, 2008

Appl. No.:

12/100008

Inventors:

Ernest S. Smith - Ontario NY, US
Leslie A. Croy - Lakeville NY, US
Maria G. M. Scrivens - Rochester NY, US

Assignee:

Vaccinex, Inc. - Rochester NY

International Classification:

A61K 39/395

US Classification:

4241451, 53038823

Abstract:

The invention relates to antibodies which bind to tumor necrosis factor α (TNFα) and uses thereof, in particular in the diagnosis and treatment of autoimmune diseases, e. g. rheumatoid arthritis (RA). Specific human monoclonal antibodies which inhibit TNFα-mediated signalling pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human monoclonal antibodies which block the ability of TNFα to bind to its receptor, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating autoimmune diseases, e. g. rheumatoid arthritis (RA), using antibodies of the invention.

US Patent:

7858559, Dec 28, 2010

Filed:

Nov 14, 2001

Appl. No.:

09/987456

Inventors:

Maurice Zauderer - Pittsford NY, US
Ernest S. Smith - Ontario NY, US

Assignee:

University of Rochester - Rochester NY

International Classification:

C40B 20/08
C40B 30/04
C40B 40/02
C40B 40/06
C40B 40/10
C40B 50/06
C12N 5/00
C07K 16/00
C12N 15/00

US Classification:

506 9, 506 6, 506 14, 506 16, 506 18, 506 26, 4353201, 435325, 5303871

Abstract:

The present invention relates to a high efficiency method of expressing immunoglobulin molecules in eukaryotic cells. The invention is further drawn to a method of producing immunoglobulin heavy and light chain libraries, particularly using the trimolecular recombination method, for expression in eukaryotic cells. The invention further provides methods of selecting and screening for antigen-specific immunoglobulin molecules, and antigen-specific fragments thereof. The invention also provides kits for producing, screening and selecting antigen-specific immunoglobulin molecules. Finally, the invention provides immunoglobulin molecules, and antigen-specific fragments thereof, produced by the methods provided herein.

US Patent:

7919095, Apr 5, 2011

Filed:

Aug 3, 2007

Appl. No.:

11/882751

Inventors:

Ernest S. Smith - Ontario NY, US
Wei Wang - Pittsford NY, US

Assignee:

Vaccinex, Inc. - Rochester NY

International Classification:

A61K 39/395
C07K 16/24

US Classification:

4241451, 4241411, 5303881, 53038823

Abstract:

The present invention provides novel monoclonal antibodies that bind specifically to IL-6. The antibodies of the invention comprise a variable heavy chain (VH) region selected from any of the VH regions disclosed herein as well as amino acid variants thereof, and/or a variable light chain (VL) region selected from any of the VL regions disclosed herein as well as amino acid variants thereof. The invention also provides methods of treating diseases and disorders associated with IL-6 expression and/or activity.

US Patent:

7919594, Apr 5, 2011

Filed:

Feb 13, 2008

Appl. No.:

12/030356

Inventors:

Ernest S. Smith - Ontario NY, US
Maurice Zauderer - Pittsford NY, US

Assignee:

Vaccinex, Inc. - Rochester NY

International Classification:

C12P 21/08
C07K 16/00
C07K 17/00
A61K 39/395
A61K 39/00

US Classification:

5303873, 4241301, 4241331, 4241411, 4241781, 5303871, 5303881, 5303911

Abstract:

Compositions and methods are provided for treating diseases associated with CD100, including certain types of cancers, autoimmune diseases, inflammatory diseases including central nervous system (CNS) and peripheral nervous system (PNS) inflammatory diseases, transplant rejections, and invasive angiogenesis. Compositions include anti-CD100 antibodies capable of binding to a soluble human CD100 antigen or a CD100 antigen located on the surface of a human CD100-expressing cell, wherein the antibody has CD100 blocking activity that is achieved by having at least one optimized CDR or FWR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD100 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD100 antibodies.

US Patent:

8496938, Jul 30, 2013

Filed:

May 7, 2010

Appl. No.:

12/776187

Inventors:

Ernest S. Smith - Ontario NY, US
Terrence Lee Fisher - Rochester NY, US

Assignee:

Vaccinex, Inc. - Rochester NY

International Classification:

A61K 39/395
A61K 39/00

US Classification:

4241451, 4241331, 4241341, 4241361, 4241781, 4241811

Abstract:

Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.